
Trendy weight-loss drugs appear to increase the risk of a rare and potentially blinding eye condition, a new study warns. People with diabetes prescribed semaglutide (Ozempic, Wegovy) were more than four times more likely to be diagnosed with NAION, researchers reported July 3 in the journal JAMA Ophthalmology. Further, those who were overweight were more than seven times more likely to be diagnosed with NAION, results showed. “The use of these drugs has exploded throughout industrialized countries and they have provided very significant benefits in many ways, but future discussions between a patient and their physician should include NAION as a potential risk,” said lead researcher Dr. Joseph Rizzo, director of the Neuro-Ophthalmology Service at Mass Eye and Ear in Boston. “It is important to appreciate, however, that the increased risk relates to a disorder that is relatively uncommon,” he added in a hospital news release. NAION typically causes sudden vision loss in one eye, without any pain, Rizzo said. It’s thought to be caused by reduced blood flow to the front of the optic nerve, where the nerve meets the eye. NAION is the most common cause of sudden blindness due to damage of the optic nerve, and is second only to glaucoma as an overall cause of optic nerve blindness, researchers said. There currently are no effective treatments for NAION, and vision loss… read on > read on >